Phase 3 Clinical Trials With Primary Completion Dates in November 2020

This is a list of Phase 3 trials with primary completion dates in November 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ADMSAdamas Pharmaceuticals, Inc.2020-11-01Phase 3NCT03567057A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
APREAprea Therapeutics, Inc.2020-11-01Phase 3NCT03745716APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
ATRAAtara Biotherapeutics, Inc.2020-11-01Phase 3NCT03394365Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
ATRAAtara Biotherapeutics, Inc.2020-11-01Phase 3NCT03392142Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab
CPHIChina Pharma Holdings, Inc.2020-11-01Phase 3NCT03660059A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
EBSEmergent BioSolutions Inc.2020-11-01Phase 3NCT03877926VELOCITY: An Anthrax Vaccine Clinical Study
FULCFulcrum Therapeutics, Inc.2020-11-01Phase 3NCT04511819Losmapimod Safety and Efficacy in COVID-19
HLUYYH. Lundbeck A/S2020-11-01Phase 3NCT03548584A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
IRWDIronwood Pharmaceuticals, Inc.2020-11-01Phase 3NCT03561883Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
NEPHNephros, Inc.2020-11-01Phase 3NCT03644264PA21 Safety and Efficacy in Adult Chinese Subjects
OVIDOvid Therapeutics Inc.2020-11-01Phase 3NCT04106557A Study of OV101 in Individuals With Angelman Syndrome (AS)
SPPISpectrum Pharmaceuticals, Inc.2020-11-01Phase 3NCT02563561A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT
TEVATeva Pharmaceutical Industries Limited2020-11-01Phase 3NCT03879837Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
TGTXTG Therapeutics, Inc.2020-11-01Phase 3NCT02612311Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
UROVUrovant Sciences Ltd.2020-11-01Phase 3NCT03902080Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
VNDAVanda Pharmaceuticals Inc.2020-11-01Phase 3NCT04140695Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)